US
USJ.F USANA Health Sciences Inc
- Market cap
- EUR 212M
- P/E
- -
- P/B
- 0.45x
- ROE
- -5.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is USJ.F undervalued?
Graham numberThe Graham number of USANA Health Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
USANA Health Sciences Inc fundamental analysis
No fundamental analysis for USANA Health Sciences Inc yet.
USANA Health Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About USANA Health Sciences Inc
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group begi…
Full company profileUSANA Health Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
USANA Health Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.01B | 1.05B | 1.19B | 1.06B | 1.13B | 1.19B | 999M | 921M | 855M | 925M | 947M |
| Gross Profit | 826M | 868M | 989M | 873M | 926M | 969M | 805M | 744M | 693M | 724M | 731M |
| Operating Income | 139M | 133M | 188M | 146M | 176M | 170M | 108M | 93.1M | 66.3M | 50.9M | 46.0M |
| EBITDA | - | 151M | 208M | 174M | 201M | - | 130M | 123M | 98.9M | 82.1M | 31.5M |
| Net Income | 100M | 62.5M | 126M | 101M | 125M | 117M | 69.4M | 63.8M | 42.0M | 10.8M | -28.8M |
| EPS | - | 2.60 | 5.36 | 4.64 | 5.93 | 5.99 | 3.61 | 3.33 | 2.20 | 0.59 | -1.56 |
| Balance Sheet | |||||||||||
| Total Assets | 471M | 519M | 554M | 517M | 641M | 578M | 597M | 633M | 748M | 743M | 703M |
| Total Liabilities | 145M | 156M | 163M | 165M | 199M | 183M | 162M | 136M | 162M | 157M | 132M |
| Shareholders' Equity | 325M | 363M | 391M | 352M | 442M | 395M | 434M | 497M | 532M | 533M | 526M |
| Cash & Short-term Investments | 176M | 247M | 214M | 235M | 312M | 240M | 288M | 330M | 182M | 158M | 169M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 137M | 124M | 152M | 127M | 160M | 121M | 104M | 85.1M | 61.0M | 22.3M | 66.2M |
| Capital Expenditure | 32.7M | 13.2M | 11.4M | 16.6M | 15.1M | 12.8M | 10.4M | 10.5M | 10.1M | 13.8M | 11.6M |
| Free Cash Flow | - | 111M | 141M | 110M | 145M | 108M | 93.5M | 74.6M | 50.9M | 8.53M | 54.6M |
| Ratios | |||||||||||
| ROE | 30.8% | 17.2% | 32.3% | 28.6% | 28.2% | 29.5% | 16.0% | 12.8% | 7.9% | 2.0% | -5.5% |
| ROA | 21.3% | 12.0% | 22.8% | 19.4% | 19.5% | 20.2% | 11.6% | 10.1% | 5.6% | 1.4% | -4.1% |
| Net Profit Margin | 9.9% | 6.0% | 10.6% | 9.5% | 11.0% | 9.8% | 6.9% | 6.9% | 4.9% | 1.2% | -3.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
USANA Health Sciences Inc dividends
USANA Health Sciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Nov 23, 2016.
Who owns USANA Health Sciences Inc
- Insiders 40.94%
- Institutions 58.61%
- Public & others 0.45%
- Shares outstanding 18.5M
- Free float 9.93M
USANA Health Sciences Inc company profile
- Company name
- USANA Health Sciences Inc
- Ticker
- USJ.F
- Exchange
- Frankfurt Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 1,570
- Fiscal year end
- December
- Address
- 3838 West Parkway Boulevard, Salt Lake City, UT, United States, 84120
- Phone
- 801 954 7100
- Website
- usana.com
About USANA Health Sciences Inc
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
USANA Health Sciences Inc management
10- Mr. Kevin G. GuestCEO & Executive Chairman · born 1963
- Mr. G. Douglas HekkingChief Financial Officer · born 1970
- Mr. Walter NootChief Operating Officer · born 1966
- Mr. P. Joshua Foukas J.D.Chief Legal Officer, General Counsel & Corporate Secretary · born 1976
- Mr. Brent L. NeidigChief Commercial Officer · born 1984
- Dr. Myron W. Wentz Ph.D.Founder & Chairman Emeritus · born 1941
- Dr. John CuomoExecutive Director of Product Development & Technology
- Mr. Peter BenedictChief Information Officer
- Dr. Kathryn Armstrong Ph.D.Chief Scientific Officer · born 1981
- Mr. Patrique RichardsExecutive Director of Investor Relations & Business Development